Cardio-kidney-metabolic phenotypes determine residual cardiovascular risk after acute coronary syndromes

View at publisher Summarise with VIRAT
Authors: Y Wang, Marianne Zeller, Deepak L. Bhatt, Maud Maza, G G Camici, Yves Cottin, Frederic Chague, Thomas Felix Lüscher, Simon C Kraler
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Residual cardiovascular risk reflects a complex interplay of lipid, low-grade inflammatory, and cardio-kidney-metabolic (CKM) pathways. In patients with acute coronary syndromes (ACS), this risk remains substantial despite intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy.1,2 A more holistic understanding of ACS patient phenotypes is required to allow for more targeted interventions.3,4 Purpose To identify ACS phenotypes by machine-learning (ML) and determine their individual contributions to residual cardiovascular risk. Methods We analysed 4,787 Swiss statin-treated acute coronary syndrome (ACS) patients from the Special Programme University Medicine Acute Coronary Syndrome (SPUM-ACS) study and 15,283 French statin-treated ACS patients from the obseRvatoire des Infarctus de Côte-d’Or (RICO) study. By using the Davies–Bouldin index and silhouette coefficient, unsupervised ML identified four patient clusters (k = 4) across lipid, inflammatory, and CKM domains. One-year major adverse cardiovascular events (MACE) were compared across phenotypes using Kaplan–Meier and multivariable Cox analyses. Results In SPUM-ACS, four patient clusters were identified by unsupervised ML, namely HDL-, LDL-, HbA1c-, and CRP–creatinine–dominant patient phenotypes (Fig. 1A). In RICO, similar clusters were identified (Fig. 1B). Risk of 1-year MACE differed significantly across clusters (log-rank p < 0.001) in both Swiss and French patients (Fig. 1C-D), manifested as a 2.45- (adjusted hazard ratio [aHR], 2.45, 95% CI 1.64–3.66) and 2.40-fold (aHR, 2.40, 95% CI 1.60–3.59) higher MACE risk for HbA1c- and CRP-creatinine-dominant phenotypes, respectively, while LDL- (aHR, 1.07, 95% CI 0.68–1.69) and HDL-dominant (reference) phenotypes showing the best outcomes among statin-treated patients (Fig. 1E-F). Expectedly, the proportion of patients exceeding guideline-recommended risk thresholds differed significantly across clusters, irrespectively whether Swiss or French patients were analyzed (Fig. 2A-B). Conclusions ML-derived unsupervised clustering identifies reproducible CKM phenotypes with distinct risk profiles, providing a foundation for phenotype-guided secondary prevention strategies in the contemporary era.For image description, please refer to the figure legend and surrounding text. For image description, please refer to the figure legend and surrounding text.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Diabetes Cardiovascular Risks and Lipoproteins Acute Myocardial Infarction Research

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN